Last year at ASH, everyone was anticipating FDA approval of carfilzomib (Kyrpolis) and pomalidomide (Pomalyst). It felt a lot like it does now, expecting the first two myeloma related immunotherapies, elotuzumab and daratumumab, to be approved within the next six months. I remember several high profile myeloma specialists (the IMF's Dr. Durie and Dana-Farber's Dr.
He's back! My dear friend and spiritual leader, Danny Parker, has had a tough year. After some subtle arm twisting, Danny agreed to share his experiences with our MMB readers: Thoughts from the Edge of Relapse Pat has been asking me in recent weeks to say something about my disappearance from the myeloma world. Of
Pattie and I don't mess around! Most of the boxes are unpacked and we're getting settled in to our new home. The renovations are dragging along; nothing we can do about that. New pool is seven weeks late and counting. The whole is dug, concrete is in and everything is plumbed and wired. That leaves
No ASCO blockbusters. Some significant data was presented. But as I mentioned yesterday, nothing time sensitive. So today I would like to write briefly about what could be a life changing meeting tomorrow at Mayo Clinic. OK, I'll admit it. I'm apprehensive about my appointment with my new myeloma specialist, Dr. Roy. My first impressions
As I mentioned in a post on May 21, we have planned three moving days. The first was a preliminary move to get needed tools, bedding and that sort of thing over to the new "fixer" on Fernandina Beach. Today's is "the big one;" three strong guys and a big truck. And the third? My
It's an awesome Friday morning! I'm both delighted and relieved. Delighted that our University of Wisconsin basketball team won again last night, advancing to the NCAA Tournament's Elite Eight; the Badgers play Arizona Saturday to see which team will advance to the Final Four. And I'm relieved to report even better news: I learned yesterday
I hadn't planned to write a follow up post about me today. But I can tell from the flood of emails and comments I've been getting that some readers are concerned I'm sitting back and not doing enough to battle my relapse. And there does seem to be some confusion about my treatment plan moving
A month ago I wrote a post explaining why my doctors and I had agreed to give Revlimid one more shot before moving on to a new therapy: RVD; do your magic one more time! It's now been almost six weeks, and I have the first SPEP results since my radiation oncologist discovered several
I concluded Saturday's post this way: "Tomorrow I will reveal what my topnotch medical team decided to try and knock my myeloma back into submission. Here's a hint: I was pleasantly surprised; it was a unanimous decision!" In past posts--and this month's Myeloma Beacon column--I had expressed concern that my healthcare team and I were
I know Thanksgiving is primarily an American, secular holiday. Honestly, that is one of the things I like best about the day. Everyone can celebrate Thanksgiving–no matter what their religion or political views. That's the way I ended my Thanksgiving post back in 2011. I had relapsed again earlier in the year and just learned
Thursday afternoon I met with my myeloma specialist, Dr. Melissa Alsina. I have had a standing appointment with her every three months since before I went into remission--and quickly bounced-out ten weeks later--one year ago. But this visit was different. It was to be a fateful one; a turning point. Due to significantly reduced cellularity
Our very own Myeloma Cinderella explores one of the four or five key controversial questions about myeloma therapy strategies this weekend: whether to use the newest and best drugs up-front, or keep them in reserve for relapse. The title of her column leaves no doubt about how suzierose feels: MYELOMA CINDERELLA: "NO ROLE FOR KEEPING
Two weeks ago I referenced a visit I had with my myeloma specialist, Dr. Melissa Alsina at Moffitt Cancer Center in Tampa. But I never followed-up with any details. The President makes a State of the Union speech each year in January. Without nearly as much pomp and circumstance, here's an update on my current
ASH is the largest hematological conference in the world. More myeloma related research results are published and presented at ASH than at any other time. But most of the information there isn't time sensitive. As I may have already mentioned, I can see progress being made. But in small, incremental steps. So I'm going to
I can best describe my last month or so as typical for a lot of myeloma patients: Up and Down. As you probably already know, late last month my myeloma specialist confirmed what my medical oncologist had been telling me since June. Our consolidation therapy had worked and my M-spike was gone. That's great news!
A reader emailed me and asked, "How do you feel?" My response: "It depends on the day." I started writing this piece Wednesday evening. All things considered, it could always be a lot worse! But Wednesday's are infusion day. Velcade, Revlimid and dexamethasone, all rolled-into one fun-fulled night. It starts with my sub-q Velcade injection
It has now been eleven months since my stem cells were infused back into my body, following high dose chemo on July 1st last year. I actually felt better three or four months out than I do now. That’s because I hadn’t started RVD (Revlimid/Velcade/dexamethasone) consolidation therapy yet. My oncologists started hitting me hard
I ended Tuesday's heartfelt, personal post this way: "But tomorrow I would like to share how I feel about my new, perpetual life on chemotherapy. How I’m not recovering as quickly as I did before my SCT. And why I am gong to call my new maintenance therapy “RVD light!” Because that’s all it is–the
Yesterday I closed my post with this cryptic statement: I was going to share the news about my visit with my myeloma specialist, Dr. Alsina today. I will get to that tomorrow. No tease–the news was sort of no news at all. Let’s just say I’m sentenced to a life of perpetual post SCT chemo.
The Myeloma Beacon's Virginia Li wrote an interesting report late last week, highlighting how "more is not necessarily better" when it comes to myeloma therapy. Here is the first part of her article: Among Velcade-Based Combinations, Four-Drug Combo Is Not More Effective Than Similar Three-Drug Combos For Newly Diagnosed Multiple Myeloma The results of a